Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Digital Health
Digital Health · The big question

Upgraded medical AI can now request and analyze diverse diagnostic data.

Advancing conversational diagnostic AI with multimodal reasoning

Nature Medicine1 min readAI-assisted summary
Editorial illustration for Advancing conversational diagnostic AI with multimodal reasoning
Editorial illustration

Summary

Imagine chatting with a computer program that not only understands your symptoms but can also act like a medical detective. Researchers have developed a specialized artificial intelligence called the Articulate Medical Intelligence Explorer, or AMIE. This system is a large language model, which is a type of AI trained on vast amounts of text to understand and generate human language. Unlike general conversational programs, AMIE is custom-built specifically to hold diagnostic conversations with patients.

Recent upgrades have given AMIE a powerful new set of skills. The AI can now handle multimodal medical data, meaning it can process different kinds of information at the same time. Instead of just passively receiving a list of symptoms, the upgraded system can actively ask for specific medical data, interpret those results, and use that combined information to logically think through a potential diagnosis.

Why it matters.

This development represents a fascinating step toward creating more capable and interactive medical assistants. By combining the ability to chat with patients and analyze multiple types of medical data, tools like AMIE could eventually help health care providers piece together complex medical puzzles more efficiently. This kind of technology might one day support doctors in busy clinics by gathering detailed preliminary information and mapping out potential next steps.

However, it is crucial to view these early advancements with caution. The current reports on this updated model do not provide specific numbers regarding its diagnostic accuracy, the size of the patient groups tested, or how well the system performs in real hospitals. Until researchers publish robust, real-world clinical validation, this upgraded AI remains a promising experimental concept rather than a fully proven medical tool.

From the source

The story in numbers.

Diagnostic large language model evaluated (AMIE)
1
Quantitative clinical metrics or sample sizes reported in text
0
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Digital Health

New AI Tool Uses Retinal Scans to Detect Multiple Diseases

Researchers have developed a new artificial intelligence system designed to detect multiple diseases just by analyzing images of the eye. Known as Reti-Pioneer, this computer program examines scans of the retina, the light-sensitive tissue at the back of the eye. By reviewing these pictures, the AI can check for signs of several different health conditions all at once. To build this tool, the research team trained the AI using a massive collection of eye images gathered from various healthcare centers, ranging from local community clinics to large, specialized hospitals. This broad mix of data helps ensure the program works well for different types of patients. The creators then tested the system using outside data, confirming that it performs reliably beyond the original images it was trained on. The system has already been put to the test in real healthcare settings. Through an initial pilot study and a silent trial, where the AI ran in the background without affecting patient care, researchers showed that the tool is fast and practical for doctors to use. However, the study does not yet specify exactly which diseases the AI targets, the exact number of patients tested, or the precise accuracy rates of the diagnoses.

Nature Medicine1 min read
Digital Health

A popular AI chatbot for doctors is setting its sights on hospitals

Over the past few years, a health technology company called OpenEvidence has captured the attention of the medical community by offering a free artificial intelligence chatbot. The tool is powered by a large language model, which is a type of artificial intelligence trained on vast amounts of text to understand and generate human-like responses. OpenEvidence designed its specific model to help doctors navigate complex patient care decisions. Rather than trying to sell this software to hospital administrators, the company offered it directly to medical professionals. The approach was a massive hit. OpenEvidence claims that about 650,000 active physicians in the United States now use the platform, with medical trainees being particularly frequent users. Now, the company is attempting a major strategic shift. After building a huge user base of individual doctors, OpenEvidence is pivoting to target large hospitals and health institutions directly.

STAT News1 min read
Digital Health

Supreme Court Preserves Telehealth Access to Mifepristone for Now

The Supreme Court has decided that mifepristone, a key medication used in medical abortions, can still be prescribed through telehealth and delivered by mail for the time being. This decision reverses a recent ruling by the 5th Circuit Court of Appeals, which had attempted to temporarily block doctors from prescribing the medication remotely. The legal dispute centers on safety protocols known as Risk Evaluation and Mitigation Strategies. Originally, these rules required patients to obtain mifepristone in person, but the Food and Drug Administration lifted those specific restrictions in 2021 to allow remote prescribing. The state of Louisiana is currently challenging this change in court, arguing that allowing doctors to prescribe the drug via telehealth directly undermines the state's strict abortion ban. It is important to note that the current Supreme Court decision is only a temporary measure. The broader case will continue to move its way through the justice system, meaning the ultimate legality of telehealth distribution for mifepristone remains highly uncertain.

STAT News1 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗